In a report issued on November 29, Sam Slutsky from LifeSci Capital maintained a Buy rating on Catalyst Biosciences (CBIO – Research Report). The company's shares closed last Tuesday at $1.20, close to its 52-week low of $1.17. According to TipRanks.com, Slutsky is a 3-star analyst with an average return of 3.0% and a 36.8% success rate. Slutsky covers the Healthcare sector, focusing on stocks such as Ventyx Biosciences, Sierra Oncology, and BELLUS Health. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Catalyst Biosciences with a $4.00 average price target.
https://www.tipranks.com/news/blurbs/lifesci-capital-thinks-catalyst-biosciences-stock-is-going-to-recover-2?utm_source=advfn.com&utm_medium=referral
Catalyst Biosciences (NASDAQ:CBIO)
Historical Stock Chart
From Dec 2021 to Jan 2022 Click Here for more Catalyst Biosciences Charts.
Catalyst Biosciences (NASDAQ:CBIO)
Historical Stock Chart
From Jan 2021 to Jan 2022 Click Here for more Catalyst Biosciences Charts.